Anupam Rama
Stock Analyst at JP Morgan
(3.57)
# 898
Out of 4,761 analysts
248
Total ratings
43.37%
Success rate
7.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $19 → $21 | $7.68 | +173.44% | 3 | Feb 6, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $66 → $36 | $18.59 | +93.65% | 10 | Dec 19, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $105 → $102 | $42.59 | +139.49% | 2 | Nov 21, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $33 → $38 | $16.38 | +131.99% | 8 | Nov 21, 2024 | |
| COGT Cogent Biosciences | Maintains: Overweight | $19 → $21 | $8.00 | +162.50% | 4 | Nov 14, 2024 | |
| SLDB Solid Biosciences | Maintains: Overweight | $15 → $12 | $5.78 | +107.61% | 6 | Nov 12, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Overweight | $16 → $17 | $9.19 | +84.98% | 13 | Nov 12, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Underweight | n/a | $1.25 | - | 7 | Nov 11, 2024 | |
| VERA Vera Therapeutics | Maintains: Overweight | $72 → $75 | $28.58 | +162.42% | 8 | Nov 5, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $39 → $40 | $20.02 | +99.80% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $38 → $44 | $33.78 | +30.25% | 11 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $79.49 | +57.25% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.50 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $13.98 | +21.60% | 7 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $23 | $21.98 | +4.64% | 3 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $64 → $57 | $27.52 | +107.12% | 15 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $64 → $68 | $58.25 | +16.74% | 5 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $31 | $4.99 | +521.24% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $66 | $21.85 | +202.06% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $43 | $36.85 | +16.69% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $173 → $181 | $120.69 | +49.97% | 16 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $10 | $7.31 | +36.80% | 7 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $38 → $36 | $12.43 | +189.62% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.75 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $177 → $175 | $106.28 | +64.66% | 11 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $0.78 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $2.81 | +362.63% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.63 | - | 2 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $0.61 | +1,374.93% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $4.45 | - | 6 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.61 | - | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $7.11 | +3,416.17% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.52 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $50.26 | +15.40% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $9.32 | +28.82% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $9.57 | +286.62% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $38.75 | +41.94% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.41 | +1,885.82% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $35.22 | +53.32% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.41 | +10,926.71% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $14.01 | +92.72% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $7.41 | +439.81% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $250.59 | -45.33% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $5.72 | +581.82% | 1 | Dec 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $6.59 | +628.38% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $13.33 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $0.95 | +1,794.74% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.83 | +1,539.34% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $50.69 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.82 | - | 2 | Jul 21, 2017 |
ORIC Pharmaceuticals
Feb 6, 2025
Maintains: Overweight
Price Target: $19 → $21
Current: $7.68
Upside: +173.44%
AnaptysBio
Dec 19, 2024
Maintains: Overweight
Price Target: $66 → $36
Current: $18.59
Upside: +93.65%
Ultragenyx Pharmaceutical
Nov 21, 2024
Maintains: Overweight
Price Target: $105 → $102
Current: $42.59
Upside: +139.49%
Syndax Pharmaceuticals
Nov 21, 2024
Maintains: Overweight
Price Target: $33 → $38
Current: $16.38
Upside: +131.99%
Cogent Biosciences
Nov 14, 2024
Maintains: Overweight
Price Target: $19 → $21
Current: $8.00
Upside: +162.50%
Solid Biosciences
Nov 12, 2024
Maintains: Overweight
Price Target: $15 → $12
Current: $5.78
Upside: +107.61%
Amicus Therapeutics
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $9.19
Upside: +84.98%
RAPT Therapeutics
Nov 11, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.25
Upside: -
Vera Therapeutics
Nov 5, 2024
Maintains: Overweight
Price Target: $72 → $75
Current: $28.58
Upside: +162.42%
Kiniksa Pharmaceuticals International,
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $20.02
Upside: +99.80%
Oct 21, 2024
Maintains: Overweight
Price Target: $38 → $44
Current: $33.78
Upside: +30.25%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $79.49
Upside: +57.25%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $1.50
Upside: -
Sep 24, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $13.98
Upside: +21.60%
Sep 13, 2024
Maintains: Overweight
Price Target: $20 → $23
Current: $21.98
Upside: +4.64%
Sep 13, 2024
Maintains: Overweight
Price Target: $64 → $57
Current: $27.52
Upside: +107.12%
Sep 4, 2024
Maintains: Overweight
Price Target: $64 → $68
Current: $58.25
Upside: +16.74%
Aug 8, 2024
Maintains: Overweight
Price Target: $33 → $31
Current: $4.99
Upside: +521.24%
Aug 8, 2024
Maintains: Overweight
Price Target: $69 → $66
Current: $21.85
Upside: +202.06%
Aug 7, 2024
Maintains: Overweight
Price Target: $46 → $43
Current: $36.85
Upside: +16.69%
Aug 7, 2024
Maintains: Overweight
Price Target: $173 → $181
Current: $120.69
Upside: +49.97%
Aug 6, 2024
Maintains: Neutral
Price Target: $12 → $10
Current: $7.31
Upside: +36.80%
Aug 6, 2024
Maintains: Overweight
Price Target: $38 → $36
Current: $12.43
Upside: +189.62%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.75
Upside: -
May 3, 2024
Maintains: Overweight
Price Target: $177 → $175
Current: $106.28
Upside: +64.66%
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $0.78
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $2.81
Upside: +362.63%
Dec 22, 2023
Downgrades: Underweight
Price Target: n/a
Current: $9.63
Upside: -
Aug 16, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $0.61
Upside: +1,374.93%
Jul 25, 2023
Downgrades: Underweight
Price Target: n/a
Current: $4.45
Upside: -
Nov 10, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.61
Upside: -
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $7.11
Upside: +3,416.17%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.52
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $50.26
Upside: +15.40%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $9.32
Upside: +28.82%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $9.57
Upside: +286.62%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $38.75
Upside: +41.94%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $1.41
Upside: +1,885.82%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $35.22
Upside: +53.32%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.41
Upside: +10,926.71%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $14.01
Upside: +92.72%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $7.41
Upside: +439.81%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $250.59
Upside: -45.33%
Dec 24, 2019
Initiates: Overweight
Price Target: $39
Current: $5.72
Upside: +581.82%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $6.59
Upside: +628.38%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $13.33
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $15 → $18
Current: $0.95
Upside: +1,794.74%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $1.83
Upside: +1,539.34%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $50.69
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $1.82
Upside: -